Although the exact mechanisms of DBS are still poorly understood, it is well established that its benefit is closely linked to the responsiveness of motor
Motor off-states are characterised by abnormal increases in the neuronal firing of the STN, which drives the inhibitory output nuclei of the basal ganglia, internal globus pallidus and substantia nigra pars reticulata. The increased gamma-aminobutyric acid (GABA)-ergic output of these nuclei inhibits thalamocortical and brainstem motor pathways and causes akinesia.
Opposite changes in firing rate and additional abnormalities in the patterning of neuronal activity are observed during dyskinetic on-states. Although the exact mechanisms of DBS are still poorly understood, it is well established that its benefit is closely linked to the responsiveness of motor Novel Treatment Options for Advanced Parkinson's Disease a report by symptoms to levodopa. After surgery, on average 60% of the dopaminergic drug dosage can be replaced by stimulation and approximately 10% of patients no longer require any levodopa therapy. 3 Interestingly, the sensitisation phenomenon leading to dyskinesia is reversible by DBS, as was demonstrated in patients who no longer exhibited the same amount of dyskinesia in response to a levodopa challenge after one year of treatment. 4 Whether this is a consequence of the secondary changes in medical therapy or of continuous electrical stimulation itself remains undetermined.
Recently, continuous delivery of a gel formulation of levodopa/carbidopa into the duodenum via a percutaneous tube and a portable pump has become commercially available in several European countries. The continuous duodenal infusion provides more constant levodopa plasma levels than oral therapy because it circumvents the problems of gastric emptying and unpredictable absorption in the small bowel. It is an alternative to intravenous administration of levodopa, which is impractical because the drug is hydrophopic and requires very large liquid volumes to dissolve. Duodenal levodopa infusion is an advanced treatment for patients with severe motor fluctuations or dyskinesia. Levodopa responsiveness is the most important prerequisite for a benefit from this infusion therapy. The same principal selection criteria apply to DBS-STN.
There are still no comparative trials of these two invasive treatment options. However, some published data and clinical experience suggest that there may be subgroups of PD patients who might be more suitable for either duodenal levodopa infusion or DBS. The following sections will summarise the evidence for both therapies and provide practical advice on how to individualise treatment decisions in patients with advanced PD and motor complications.
Deep Brain Stimulation
Over the last two decades a firm place has been established for surgical therapies in the treatment of PD. DBS is accomplished by implanting an electrode with four contacts into the target area within the brain and connecting it to an internal pulse generator, usually located in the chest region. The stimulator settings can be adjusted telemetrically with respect to electrode configuration, current amplitude, pulse width and pulse frequency. By passing high-frequency electrical current (>100Hz) into the target area, DBS reversibly mimics the effect of lesioning the stimulated brain area. Stimulation at lower frequencies has no beneficial effects, and may even aggravate symptoms. 5 The exact cellular mechanisms of DBS are still unknown, although several hypotheses have been postulated. 6 In animal models of PD, neuronal activity is abnormally increased in the STN and These adverse events are most frequent during the first weeks after surgery and are often related to the complex interaction between drug withdrawal and stimulation adjustment during this initial stabilisation period. 9 Because STN-DBS aims at improving a patient's functional capacity and reducing disability by alleviating motor fluctuations and dyskinesia, it was important to prove that quality of life is indeed improved despite the potential adverse effects of the therapy on motor or non-motor domains.
This fundamental question was addressed by a recent randomised, controlled, multicentre study comparing neurostimulation with best medical management over a six-month period. 10 The study included 156 patients with severe motor symptoms of PD who were randomly assigned in pairs to receive either bilateral DBS-STN in combination with medical treatment or best medical therapy alone. The primary outcome of the trial was the change in health-related quality of life on the Parkinson's Disease Questionairre-39 (PDQ-39) after six months. The PDQ-39 summary improved in the surgically treated group by about 25%, but remained virtually unchanged in the medically treated patients. While serious adverse events were more common with neurostimulation than with medication alone and included a fatal intracerebral haematoma and a suicide, the total number of adverse events was higher among medication-only patients. They included typical treatment-related complications in advanced PD such as increased motor fluctuations, dyskinesia, falls or delusions. One patient in the medication-only group died from a car accident during a psychotic episode. By including a control group, this study could demonstrate for the first time that advanced PD is associated with major risks of disease or treatmentrelated complications that need to be carefully balanced against the risks of an invasive therapy. In the patients selected for this study, the benefits of STN-DBS clearly outweighed the risks in that an improvement in quality of life was indeed achieved. The durability of improved health-related quality of life has not been assessed. The open-label follow-up of several cohorts suggests that symptomatic benefits are sustained for up to five years after STN-DBS. [11] [12] [13] 29 the treatment response by age at surgery found that patients over 70 years of age had a worsening of their axial symptom scores after surgery that did not recover even with additional levodopa treatment. 14 In addition, older patients have significantly less improvement in quality of life despite experiencing symptomatic benefit from DBS as assessed by the UPDRS score. 15, 16 This has raised the question as to whether the inclusion criteria for DBS should include an age cut-off. 18 The therapy significantly shortened the daily duration of off-periods and dyskinesia and led to significant improvements in four domains (mobility, activities of daily living, stigma and bodily discomfort) of a disease-specific quality-of-life scale (PDQ-39). The average age (66-68 years) in the studies of Antonini and Nyholm was higher than in most DBS trials and suggests that duodenal infusion therapy has been offered to an older patient group that was less likely to benefit from DBS as an alternative treatment. While the principal efficacy of duodenal levodopa infusions has been established, there are fewer data on the long-term tolerance of this technically complex treatment. In our own clinical experience, application problems -such as tube dislocations, leakage or tube obstructionare more likely to cause termination of the treatment than the re-emergence of dyskinesia or motor fluctuations.
Choosing Deep Brain Stimulation or Duodenal Levodopa Infusion for Individual Patients
In a recent survey using strict inclusion and exclusion criteria only 1.6-4.5% of an unselected sample of PD patients attending the outpatient service of a movement disorder centre were found to be eligible for STN-DBS, 19 
